Stay updated on IGF-1/IGFBP3 for ROP Prevention Clinical Trial
Sign up to get notified when there's something new on the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page.

Latest updates to the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page
- Check2 days agoChange DetectedThe page shows a new Revision: v3.6.6 tag replacing the previous v3.6.5, indicating a software build update. This change affects only the page's version label and does not alter study information or navigation.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new Revision: v3.6.5 label was added and the old Revision: v3.6.4 label was removed, signaling a platform update. The change does not affect the study content or page navigation.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a new build of the page. There are no visible changes to study details or content.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3, representing a new version of the page. This is a CMS-level update and does not involve substantive changes to the study details or navigation.SummaryDifference0.0%

- Check67 days agoChange DetectedFooter now displays Revision: v3.6.2, replacing v3.6.0, indicating a small software update. This change does not affect the study text, eligibility criteria, or results presented on the page.SummaryDifference0.0%

- Check81 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment heading formatting was updated. The page now indicates recruitment is closed and the site revision was updated to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to IGF-1/IGFBP3 for ROP Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IGF-1/IGFBP3 for ROP Prevention Clinical Trial page.